[go: up one dir, main page]

PL2604625T3 - Wytwarzanie cząsteczek wiążących - Google Patents

Wytwarzanie cząsteczek wiążących

Info

Publication number
PL2604625T3
PL2604625T3 PL12186010T PL12186010T PL2604625T3 PL 2604625 T3 PL2604625 T3 PL 2604625T3 PL 12186010 T PL12186010 T PL 12186010T PL 12186010 T PL12186010 T PL 12186010T PL 2604625 T3 PL2604625 T3 PL 2604625T3
Authority
PL
Poland
Prior art keywords
preparation
binding molecules
molecules
binding
Prior art date
Application number
PL12186010T
Other languages
English (en)
Inventor
Mark Throsby
Ton Logtenberg
Kruif Cornelis Adriaan De
Original Assignee
Merus N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47010271&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2604625(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merus N.V. filed Critical Merus N.V.
Publication of PL2604625T3 publication Critical patent/PL2604625T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
PL12186010T 2011-09-26 2012-09-26 Wytwarzanie cząsteczek wiążących PL2604625T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161539116P 2011-09-26 2011-09-26
EP12186010.0A EP2604625B1 (en) 2011-09-26 2012-09-26 Generation of binding molecules

Publications (1)

Publication Number Publication Date
PL2604625T3 true PL2604625T3 (pl) 2017-12-29

Family

ID=47010271

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12186010T PL2604625T3 (pl) 2011-09-26 2012-09-26 Wytwarzanie cząsteczek wiążących

Country Status (17)

Country Link
US (6) US9145588B2 (pl)
EP (4) EP3263597A1 (pl)
AU (4) AU2012233037B2 (pl)
CA (1) CA2791109C (pl)
CY (1) CY1119717T1 (pl)
DK (1) DK2604625T3 (pl)
ES (1) ES2636239T3 (pl)
HK (1) HK1247938A1 (pl)
HR (1) HRP20171193T1 (pl)
HU (1) HUE034386T2 (pl)
LT (1) LT2604625T (pl)
ME (1) ME02817B (pl)
PL (1) PL2604625T3 (pl)
PT (1) PT2604625T (pl)
RS (1) RS56302B1 (pl)
SI (1) SI2604625T1 (pl)
SM (1) SMT201700409T1 (pl)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP2059532B1 (en) 2006-09-07 2012-12-26 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
MX368932B (es) 2009-06-26 2019-10-22 Regeneron Pharma Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original.
ES2547142T5 (es) 2010-02-08 2021-12-09 Regeneron Pharma Cadena ligera común de ratón
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
IL273982B2 (en) 2011-08-05 2023-03-01 Regeneron Pharma Humanized mice possess a universal light chain
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
HK1200849A1 (en) * 2011-12-22 2015-08-14 F. Hoffmann-La Roche Ag Full length antibody display system for eukaryotic cells and its use
CN120383672A (zh) 2012-04-20 2025-07-29 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
PT2900694T (pt) 2012-09-27 2018-11-13 Merus Nv Anticorpos de igg biespecíficos como ativadores de células t
EP3110846B1 (en) 2014-02-28 2020-08-19 Merus N.V. Antibodies that bind egfr and erbb3
IL301147A (en) 2014-02-28 2023-05-01 Merus Nv An antibody that binds to ErbB-2 and ErbB-3
BR112016021572A2 (pt) 2014-03-21 2017-10-03 Regeneron Pharma Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação
GB201500464D0 (en) 2015-01-12 2015-02-25 Crescendo Biolog Ltd Method of producing optimised therapeutic molecules
EP3271403A1 (en) 2015-03-19 2018-01-24 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
HUE042039T2 (hu) 2015-07-10 2019-06-28 Merus Nv Humán CD3 kötõ antitest
HUE055222T2 (hu) 2015-10-23 2021-11-29 Merus Nv Megkötõ molekulák, amelyek gátolják a rák növekedését
JP7082604B2 (ja) 2016-03-21 2022-06-08 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性および多機能性分子ならびにその使用
CN109640644B (zh) 2016-06-03 2021-10-26 瑞泽恩制药公司 表达外源末端脱氧核苷酸转移酶的非人动物
WO2018151820A1 (en) 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
CN110650752A (zh) 2017-03-31 2020-01-03 美勒斯公司 用于治疗具有NRG1融合基因的细胞的ErbB-2和ErbB3结合双特异性抗体
EA201992522A1 (ru) 2017-05-17 2020-04-22 Мерус Н.В. КОМБИНАЦИЯ БИСПЕЦИФИЧЕСКОГО АНТИТЕЛА К ErbB-2/ErbB-3 С ЭНДОКРИННОЙ ТЕРАПИЕЙ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
US20210246227A1 (en) 2017-05-31 2021-08-12 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
EP3665198B9 (en) 2017-08-09 2025-05-21 Merus N.V. Antibodies that bind egfr and cmet
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
US20210009711A1 (en) 2018-03-14 2021-01-14 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US20210051929A1 (en) 2018-03-24 2021-02-25 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
US11337409B2 (en) 2018-06-08 2022-05-24 Crystal Bioscience Inc. Transgenic animal for producing diversified antibodies that have the same light chain I
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
CN114127112A (zh) 2019-02-21 2022-03-01 马伦戈治疗公司 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
AU2020224154B2 (en) 2019-02-21 2025-05-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
WO2020172596A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and thereof
TW202039578A (zh) 2019-03-29 2020-11-01 荷蘭商美勒斯公司 Cd3結合分子
CN114605546A (zh) * 2019-03-29 2022-06-10 美勒斯公司 Cd3结合分子
CN114901678A (zh) 2019-12-02 2022-08-12 瑞泽恩制药公司 肽-mhc ii蛋白构建体及其用途
JP2023509708A (ja) 2020-01-03 2023-03-09 マレンゴ・セラピューティクス，インコーポレーテッド 抗ｔｃｒ抗体分子およびその使用
EP4084821A4 (en) 2020-01-03 2024-04-24 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
WO2021168274A1 (en) 2020-02-21 2021-08-26 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
KR20230028242A (ko) 2020-04-24 2023-02-28 마렝고 테라퓨틱스, 인크. T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도
IL299508A (en) 2020-07-01 2023-02-01 Ars Pharmaceuticals Inc Anti-asgr1 antibody conjugates and uses thereof
KR20230074487A (ko) 2020-08-26 2023-05-30 마렝고 테라퓨틱스, 인크. Trbc1 또는 trbc2를 검출하는 방법
WO2022046920A2 (en) 2020-08-26 2022-03-03 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
AU2021331076A1 (en) 2020-08-26 2023-04-06 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
TW202229328A (zh) 2020-09-11 2022-08-01 美商再生元醫藥公司 抗原特異性抗體之鑑定及產生
JP2024500399A (ja) 2020-12-16 2024-01-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化Ｆｃアルファ受容体を発現するマウス
IL303868A (en) 2020-12-23 2023-08-01 Regeneron Pharma Nucleic acids encoding anchor-modified antibodies and uses thereof
WO2022216993A2 (en) 2021-04-08 2022-10-13 Marengo Therapeutics, Inc. Multifuntional molecules binding to tcr and uses thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
AU751659B2 (en) 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
ATE319745T1 (de) 1997-05-21 2006-03-15 Biovation Ltd Verfahren zur herstellung von nicht-immunogenen proteinen
KR20010042329A (ko) 1998-03-30 2001-05-25 와일러 제임스 에프. 코르티코트로핀 방출 인자 수용체 1-결핍 마우스
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
DE60035434T2 (de) 1999-12-27 2008-05-15 Crucell Holland B.V. Auswahl von epitop-bindungsfähigen verbindungen aus bibliotheken
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP2294917A1 (en) 2001-03-22 2011-03-16 Abbott GmbH & Co. KG Transgenic animals expressing antibodies specific for genes of interest and uses thereof
NZ529465A (en) 2001-06-15 2005-05-27 Crucell Holland B Chimaeric phages
GB0130267D0 (en) 2001-12-19 2002-02-06 Neutec Pharma Plc Focussed antibody technology
AU2003250074B2 (en) 2002-07-18 2010-09-09 Merus N.V. Recombinant production of mixtures of antibodies
EP1439234A1 (en) 2003-01-08 2004-07-21 ARTEMIS Pharmaceuticals GmbH Targeted transgenesis using the rosa26 locus
EP2395017A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
SG128680A1 (en) 2003-07-22 2007-01-30 Crucell Holland Bv Binding molecules against sars-coronavirus and uses thereof
ATE536376T1 (de) 2003-12-23 2011-12-15 Crucell Holland Bv Humanes bindungsmolekül gegen cd1a
JP5912211B2 (ja) 2004-01-20 2016-04-27 メルス ビー．ヴィー． 結合タンパク質の混合物
ES2426725T3 (es) 2004-05-27 2013-10-24 Crucell Holland B.V. Método para identificar moléculas de unión que pueden neutralizar el virus de la rabia
EP2279749B1 (en) 2004-10-12 2015-06-10 Crucell Holland B.V. Binding molecules for detection of aml
JP4487068B2 (ja) 2004-10-12 2010-06-23 国立大学法人 岡山大学 細胞の遺伝子変異機能の制御による変異タンパク質の作製方法
WO2006051091A1 (en) 2004-11-11 2006-05-18 Crucell Holland B.V. Compositions against sars-coronavirus and uses thereof
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
WO2006117699A2 (en) 2005-04-29 2006-11-09 Innate Pharma Transgenic animals and methods of making recombinant antibodies
AU2006245734C1 (en) 2005-05-12 2012-05-24 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
US20090130652A1 (en) 2005-06-23 2009-05-21 Crucell Holland B.V. Optimization of West Nile Virus Antibodies
US8642513B2 (en) 2005-09-15 2014-02-04 Crucell Holland B.V. Method for preparing immunoglobulin libraries
PL2374818T3 (pl) 2006-06-02 2013-05-31 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
EA031202B1 (ru) 2006-06-06 2018-11-30 Янссен Вэксинс Энд Превеншн Б.В. Антитело человека, обладающее фагоцитарной активностью против стафилококков, и его применение
KR20220031126A (ko) 2006-06-06 2022-03-11 얀센 백신스 앤드 프리벤션 비.브이. 장내구균에 대한 사멸활성을 갖는 인간결합분자 및 그것의 용도
EP2059532B1 (en) 2006-09-07 2012-12-26 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
CN101522716B (zh) 2006-10-02 2013-03-20 瑞泽恩制药公司 抗人il-4受体的高亲和力人抗体
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
ITMI20071522A1 (it) 2007-07-27 2009-01-28 Areta Internat S R L Vaccino idiotipico
CA3187687A1 (en) 2007-09-14 2009-03-19 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
EP2088432A1 (en) * 2008-02-11 2009-08-12 MorphoSys AG Methods for identification of an antibody or a target
ES2445193T3 (es) 2008-06-27 2014-02-28 Merus B.V. Mamíferos no humanos productores de anticuerpos
US20120101000A1 (en) 2008-11-21 2012-04-26 Chen Zhou High complexity mammalian display library and methods of screening
SG176003A1 (en) 2009-05-11 2011-12-29 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
ES2511051T3 (es) 2009-05-29 2014-10-22 Morphosys Ag Colección de anticuerpos sintéticos para tratar enfermedades
MX368932B (es) 2009-06-26 2019-10-22 Regeneron Pharma Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original.
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
ES2547142T5 (es) 2010-02-08 2021-12-09 Regeneron Pharma Cadena ligera común de ratón
EP2572203B1 (en) * 2010-05-17 2017-10-25 The Board of Regents of The University of Texas System Determination of antigen-specific antibody sequences in blood circulation
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
CN120383672A (zh) 2012-04-20 2025-07-29 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
SMT201800435T1 (it) 2013-02-20 2018-09-13 Regeneron Pharma Animali non umani con sequenze della catena pesante dell’immunoglobulina modificate riferimento incrociato a domande correlate

Also Published As

Publication number Publication date
CA2791109A1 (en) 2013-03-26
US20130096020A1 (en) 2013-04-18
HUE034386T2 (en) 2018-02-28
US20160130367A1 (en) 2016-05-12
AU2020244368A1 (en) 2020-10-29
HRP20171193T1 (hr) 2017-12-01
EP4567048A2 (en) 2025-06-11
ME02817B (me) 2018-01-20
PT2604625T (pt) 2017-08-11
US11408095B2 (en) 2022-08-09
AU2016200316A1 (en) 2016-02-11
US12291798B2 (en) 2025-05-06
CA2791109C (en) 2021-02-16
EP2604625B1 (en) 2017-06-28
EP4086282A1 (en) 2022-11-09
RS56302B1 (sr) 2017-12-29
DK2604625T3 (en) 2017-08-21
US9908946B2 (en) 2018-03-06
HK1247938A1 (en) 2018-10-05
US20200247908A1 (en) 2020-08-06
CY1119717T1 (el) 2018-09-05
AU2018201328B2 (en) 2020-07-02
SMT201700409T1 (it) 2017-09-07
EP3263597A1 (en) 2018-01-03
AU2018201328A1 (en) 2018-03-15
LT2604625T (lt) 2017-09-25
US20250230579A1 (en) 2025-07-17
AU2012233037A1 (en) 2013-04-11
AU2016200316B2 (en) 2017-11-23
US9145588B2 (en) 2015-09-29
ES2636239T3 (es) 2017-10-05
EP4567048A3 (en) 2025-08-20
US10647781B2 (en) 2020-05-12
AU2012233037B2 (en) 2015-10-29
SI2604625T1 (sl) 2017-11-30
EP2604625A1 (en) 2013-06-19
US20180179300A1 (en) 2018-06-28
US20230160105A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
PL2604625T3 (pl) Wytwarzanie cząsteczek wiążących
HRP20181553T1 (hr) Molekule koje se vežu na anti-alfa-sinuklein
DK2771364T3 (da) Fremstilling af heterodimere proteiner
EP2675909A4 (en) GLUCOSYLSTEVIA COMPOSITION
EP2720561A4 (en) Stevia-COMPOSITION
SMT201900181T1 (it) Metodi di preparazione di coniugati
HUE041958T2 (hu) 4-IBB-t kötõ molekulák
DK2892923T3 (da) Il-18-bindingsmolekyler
EP2713762A4 (en) Stevia-COMPOSITION
BR112013023241A8 (pt) melhorias para entidades biológicas imobilizadas
HUE052485T2 (hu) RNA készítmény immunterápiára
LT2742151T (lt) Polimerazės kompozicija
BR112013022112A2 (pt) composição
BR112013022102A2 (pt) composição
DK2686017T3 (da) Oftalmisk sammensætning
BR112014012539A2 (pt) moléculas de ligação específicas para her3 e usos dessas
BR112014004395A2 (pt) composição
CO6960555A2 (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
BR112014003878A2 (pt) síntese de r-bifenilalaninol
IL231616A0 (en) Tropicalizing agent
IL225346A0 (en) Serum preparation
BR112013033808A2 (pt) composição
EP2730619A4 (en) COMPOSITION
EP2768515A4 (en) GLUCOSYLSTEVIA COMPOSITION
EP2691361A4 (en) SYNTHESIS OF DIAZIDEN